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Abstract
Background and Aim: Severe ulcerative colitis (UC) is potentially life threatening
and is associated with signiﬁcant morbidity. TNF-/ inhibitors (Inﬂiximab) were introduced in Australia for the management of medically resistant, acute, severe ﬂares of
UC in 2008. The aim of this study is to assess the efﬁcacy of Inﬂiximab in preventing
emergent and emergency colectomies for patients with moderate to severe UC by
comparing colectomy rates before and after its introduction at our institution.
Methods: This was a retrospective cohort study of all patients who were admitted to
the Royal Perth Hospital with a ﬂare of UC between 2002 and 2017. Patients were
divided into two cohorts: those admitted prior to the introduction of Inﬂiximab (pre2008) and those admitted after. We compared data between these two groups, including age, gender, length of admission, use of Inﬂiximab, colectomy, and complications
of surgery. We deﬁned emergency surgery as requiring surgery during the index
admission and emergent surgery as an operation within 54 weeks.
Results: A total of 313 UC cases from 2002 to 2017 were analyzed. There was a
decrease in emergency and emergent colectomies from 19.4 to 8% in the post-2008
cohort (P = 0.008). Furthermore, there was a decrease in the proportion of operations
performed as emergencies, from 36 to 20%. This resulted in a signiﬁcantly reduced
length of stay (13.4–9.7 days, P < 0.05) and complication rate (36 to 20%, P < 0.05).
Conclusion: Overall, the need for emergency and emergent operations has drastically
reduced at our institution with the introduction of Inﬂiximab. This study has conﬁrmed the efﬁcacy of Inﬂiximab in reducing colectomy rates at our institution.

Introduction
Ulcerative colitis (UC) is a chronic inﬂammatory disease in the
inﬂammatory bowel disease (IBD) spectrum of the colon and rectum. In Australia, the annual incidence of UC is 17.4 per
100 000, and there are currently 33 000 Australians living with
the disease.1
The pathogenesis of IBD is thought to be a result of the
dysregulation of the mucosal immune system.2 Although the
exact mechanism by which the inﬂammatory cascade is stimulated in IBD is unknown, studies have shown that TNF-/ mediates inﬂammation. TNF-α blockade has a restorative function in
the suppressive action of regulatory T-cells, which is the basis of
its use in IBD.3
The use of TNF-α inhibitors (Inﬂiximab) in the setting of
moderate to severe ﬂares of UC was approved by the Therapeutic
140

Guidelines Australia (TGA) in February 2007. Its use is highly
regulated given that the cost of a single 100-mg injection is
$507.42. To be eligible, adult patients must ﬁrst be clinically
scored by the Truelove and Witts criteria as having severe disease, have a Mayo Score of >6, or have had a positive documented response previously to TNF-/ inhibitors.
Only a few studies have directly compared the incidence
of colectomies before and after the introduction of this
drug.4There are no similar studies in an Australian context.
Pooled data from ACT-1 and -2 showed a 7% absolute risk
reduction and a hazard ratio of 0.59 for colectomies when comparing TNF-alpha inhibitor use and placebo.5,6
The aim of this study is to assess the efﬁcacy of Inﬂiximab
in preventing colectomies in the emergency setting for patients
with moderate to severe UC by comparing colectomy rates
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before and after the introduction of Inﬂiximab at an Australian
institution.

Methods
Data collection. A retrospective cohort study was undertaken of patients who were admitted to the Royal Perth Hospital
with an acute ﬂare of ulcerative colitis. The study period was
from 1 July 2002 to 1 July 2017. All admissions to the hospital
for an acute ﬂare of UC, which were biopsy proven, in patients
aged >16 years were included. Patients with Crohn’s disease,
nonspeciﬁc colitis, and all admissions where the primary diagnosis was not consistent with an acute ﬂare of UC were excluded.
Admissions were identiﬁed using The Open Web Administration System (TOPAS) and WebPAS (replaced ToPAS from
2012). The International Statistical Classiﬁcation of Diseases and
Related Health Problems 10th Revision, Australian Modiﬁcation
(ICD-10-AM) codes: K51.0 Ulcerative (acute) pancolitis; K51.2
Ulcerative (acute) proctitis; K51.3 Ulcerative (chronic) rectosigmoiditis; K51.4 Inﬂammatory polyps; K51.5 left sided colitis; K51.8 Other UC; and K51.9 UC, unspeciﬁed were used to
search this database. A total of 3117 admissions were identiﬁed.
After applying the exclusion criteria, 313 admissions were eligible for analysis.
The variables extracted during chart review included age
at admission, gender, length of admission, medication used (corticosteroids, azathioprine/ 6-MP, Ciclosporin, 5-ASA), use of
TNF-/ inhibitors, complications of TNF-/ inhibitors, colectomy, complications of surgery, and death. Each admission was
also scored according to the Truelove and Witts classiﬁcation7 as
this is the accepted criteria for approval of TNF-/ inhibitor use
in IBD and is easily extractable from medical records. If patients
underwent a colectomy, the timing was categorized as Emergency Colectomy or Emergent Colectomy (within 54 weeks of
admission). There are currently no internationally accepted deﬁnitions to distinguish semiurgent colectomies from true elective
colectomies. The 54-week mark was chosen because the ACT-1
and ACT-2 trials demonstrated the maximal efﬁcacy of
Inﬂiximab at weeks 30 and 54.8 An emergent colectomy was
therefore deﬁned as any semielective colectomy performed
within 54 weeks of an admission for acute colitis. Admissions
that eventually required an elective colectomy at the end of the
study period were also recorded for subgroup analysis. Admissions were then divided into two cohorts: pre-Inﬂiximab use
(2007 and before) and postapproval for Inﬂiximab use (2008
onward).
Statistical analysis. Frequency and proportion of
colectomies, use of Inﬂiximab, and severity of UC on admission
were assessed. Chi-square tests were used to determine if there
was any difference in the proportions of these measures prior to
and following the introduction of Inﬂiximab in 2008. Logistic
regression was then used to formally examine the relationship
between Inﬂiximab and the rate of UC before and after 2008.
Odds ratios (ORs) and conﬁdence intervals were presented as
model estimates. Data pertaining to hospital length of stay were
not normally distributed (Shapiro Wilk P < 0.001) and were logtransformed. A general linear model (GLM) was then used to
investigate whether the introduction of Inﬂiximab in 2008 had
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any impact on patient’s hospital length of stay. The age at which
UC was presented in patients and the severity of the condition
were also adjusted for and included in both the logistic regression model and the GLM. Signiﬁcance of variables was achieved
if P < 0.05.

Results
A total of 313 UC cases from 2002 to 2017 were collated and
analyzed. (Table 1). The number of UC admissions pre- and
post-Inﬂiximab was 62 and 251, respectively. The median interquartile range (IQR) age at presentation was 35.1 (27.1–47.6)
years. One in three admissions was moderate (n = 100, 32%),
while the remaining were severe (n = 213, 68%). There were no
admissions for mild ﬂares of UC.
There was a gradual increase in the number of admissions
involving the use of Inﬂiximab from 2008. In the ﬁrst 4 years
since the introduction of Inﬂiximab, one in four cases (16 of
53, 23%) involved the use of Inﬂiximab, which later increased to
one in three (19 of 55, 34.5%) cases in 2012–2013 and then to
almost one in two cases (61 of 127, 48%) from 2014 to 2017.
Furthermore, 47% (99 of 213) of all severe cases of UC involved
inﬂiximab. There was only a single instance where Inﬂiximab
was used for moderate UC. This patient had previously presented
with a severe ﬂare and had already received Inﬂiximab prior to
this admission.
Approximately 13% (n = 28) of all severe cases required
emergency or emergent colectomies, of which 71% (20 of 28)
underwent emergency surgery. Only 4% (n = 4) of patients with
moderate UC underwent surgery.
Table 1 Patient demographics
Demographics

Pre-2008 (62)

2008 onwards (251)

P value

39.8
16.5
10.8
11.9
62 (100%)
24 (38.7%)
57 (91.9%)
4 (6.5%)
9 (14.5%)

38.5
15.4
6.2
5.5
236 (94%)
101 (40.2%)
210 (83.7%)
155 (61.8%)
1 (0.4%)

0.55
0.406
0.004
<0.001
0.055
0.756
0.175
<0.001
<0.001

Age (mean)
Age (SD)
LOS (mean)
LOS (SD)
Prednisolone
Azathioprine
5-ASA
TNF-α
Ciclosporin

Table 2 Primary outcomes
Emergency/emergent
colectomy

Inﬂiximab
Severity of
UC

Preintroduction
Postintroduction
Moderate
Severe

No

Yes

P-value

50 (80.6%)
231 (92.0%)
96 (96.0%)
185 (86.9%)

12 (19.4%)
20 (8.0%)
4 (4.0%)
28 (13.1%)

0.008†
0.013†

†

Chi-square test.
UC, ulcerative colitis.
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Percentage of UC cases

n = 6, 9.7%

90%

n = 2, 3.2%

80%

n = 10, 16.1%

Table 4

n = 3, 1.2%
n = 8, 3.2%
n = 12, 4.8%

100%

List of surgical complications

Surgical
classiﬁcation Surgical complications
Emergent
Emergent
Emergency
Emergency
Emergency
Emergency
Emergency
Emergency
Emergency
Emergency

70%
60%
50%
n = 228, 90.8%

40%
n = 44, 71%

30%
20%
10%

TNF-/
Clavien-Dindo
inhibitor use
score

Small bowel perforation
Rectal stump leak
Rectal stump leak
Enterocutaneous ﬁstula
Anastomotic leak
Intra-abdominal collection
Enterocutaneous ﬁstula
Wound infection (superﬁcial)
Wound infection (superﬁcial)
Wound infection (superﬁcial)

No
Yes
No
No
No
No
Yes
Yes
Yes
Yes

3b
3b
3b
4b
3b
3b
3b
1
1
1

0%
2008 and onward

25

Figure 1 Admission requiring/not requiring surgery pre- and post2008. , elective; , emergent, , emergency; , no surgery.

From 2002 to 2007, 19.4% of UC admissions eventuated
in emergency/emergent surgery, and this decreased to only 8%
from 2008 onward (Table 2). Figure 1 illustrates the reduction in
the percentage of cases post-2008 requiring surgery in comparison to pre-2008, particularly with emergency and elective surgeries. The rate of surgery throughout the years in the post-2008
period remained low, except for during 2014–2015 (15%),
despite comparable proportions of severe cases (n = 45, 62%).
After adjusting for severity and age of patients presenting
with UC, the logistic model indicated that there was a 72%
reduction in the emergency colectomy rate (OR = 0.28,
P = 0.005) and a 62% reduction in the rate of
emergency/emergent colectomies (OR = 0.38, P = 0.017) since
the introduction of Inﬂiximab in 2008. Patients with severe UC
were 3.5–5 times more likely to undergo emergent or emergency
surgery (P < 0.05) compared to those with moderate disease. The
age at presentation had no signiﬁcant inﬂuence on the likelihood
of emergency and/or emergent surgery (P > 0.05) (Table 3).
Only 4 of 159 admissions (0.03%) receiving Inﬂiximab
had recorded related complications. Two had a severe drug reaction necessitating immediate cessation, and two had signiﬁcant
infections secondary to immunosuppression. One patient had a
peritonsillar abscess and the other oral candidiasis. Ten patients
experienced surgical complications, which ranged from superﬁcial wound infections to intra-abdominal collections (Table 4).

Table 3

Number of UC Cases

Pre-2008

20

n = 8,
36.4%

15
10

n = 14,
63.6%

5

n = 2,
20%
n = 8,
80%

n = 9,
100%

Emergent

Elective

0
Emergency

Surgery Type

Figure 2 Postcolectomy complications.
complication.

, no complication;

,

Complications were scored using the Clavien-Dindo classiﬁcation.9 Only two patients who received Inﬂiximab scored >3,
while all patients who had complications and did not receive
Inﬂiximab scored >3. Overall, there was a 36.4% rate of complications for emergency colectomies compared to 20% for emergent colectomies (Fig. 2). None of the elective operations within
these two cohorts had recorded complications. The observed
trend in the reduced complication rate was evident. (P < 0.095).
There was only one mortality, and this occurred in the pre-2008
cohort following emergency colectomy. The patient was 73 years
of age, had signiﬁcant comorbidities, and presented with a severe
ﬂare of UC.
In relation to average length of stay (aLOS), the GLM demonstrated a signiﬁcant year × severity interaction (P < 0.033),

Logistic regression modeling of emergency and emergency/emergent colectomy pre- and postintroduction of inﬂiximab in 2008
Emergency colectomy only

Variable
Inﬂiximab
Severity of UC
Age at presentation

Category

OR (95% CI)

Preintroduction
Postintroduction
Moderate
Severe
Range 15–85

1.00 (Ref)
0.28 (0.11, 0.69)
1.00 (Ref)
4.82 (1.09, 21.26)
1.01 (0.98, 1.04)

P-value

0.005
0.038
0.502

Emergency and emergent colectomy
OR (95% CI)
1.00 (Ref)
0.38 (0.17, 0.84)
1.00 (Ref)
3.47 (1.17, 10.24)
1 (0.98, 1.03)

P-value

0.017
0.024
0.773

1.00 (Ref), reference level; CI, conﬁdence interval; OR, odds ratio.
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where no signiﬁcant difference in mean aLOS was observed
between admissions pre-2008 (8.1 days; 95% CI 5.6–11 days) and
post-2008 (8.3 days, 95% CI 6.7–10 days) for moderate UC cases;
however, a signiﬁcant reduction in median length of stay (LOS)
was evident in severe UC cases post-2008 (9.7 days, 95% CI 8.3–
11.9 days) compared to pre-2008 (13.4 days, 95% CI 11.3–
15.8 days) (see Fig. 3).
Not unexpectedly, the aLOS (16.0 days, 95% CI 13.1–
19.3 days) for patients who underwent emergency surgery was
signiﬁcantly higher than those who had emergent (8.9 days, 95%
CI 5.8–12.4 days) (P = 0.007) or medical management (5.7 days,
95% CI 5.0–6.4 days) (P < 0.001). The aLOS is also positively
correlated with the age at presentation of UC (P < 0.001).

Discussion
This study conﬁrms the efﬁcacy of Inﬂiximab in reducing emergent
and emergency colectomy rates. Prior to the introduction of TNF-α
inhibitors, the emergency and emergent colectomy rate at our
institution was 19.4%. Our results have shown a signiﬁcant
decline in the rate of emergency and emergent colectomies performed at our institution to 8% post-2008, which is comparable to
other studies.4,6,10,11 There have been no prior studies on the efﬁcacy of TNF-/ inhibitors in preventing colectomies in Australia.
Although an overall reduction in both emergency and
emergent operations was observed, there was also a lower proportion of patients requiring emergency surgery. In the preInﬂiximab era, the proportion of emergency to emergent operations was 2 to 1. This has changed in the post-Inﬂiximab era to
1.5 to 1. This meant an increased opportunity for laparoscopic
surgery while minimizing LOS, complications, and mortality,
which is more achievable in the semielective setting.12 There
was also a noticeable reduction in the rate of complications from
36% in emergency operations to 20% in emergent operations,
and no complications were identiﬁed in elective procedures. It is
for this reason that we believe the differentiation between emergency and emergent colectomies was important.
It is well established that emergency colectomies in IBD
are associated with signiﬁcantly higher morbidity and mortality
compared to the elective setting.12,13 Compounding this, the estimated annual hospital cost for the treatment of IBD in Australia

Length of Stay (days)

18

is up to $100 million per annum.14 As such, this is an important
cohort of patients to study.
Although licensed for use in 2008, there was a gradual
increase in its use observed over the following years. This is likely
due to an increased awareness among prescribers and availability of
the drug. In 2013, a specialist referral unit for IBD was established
at this institution, which also saw a rise in the number of referrals
and admissions. This may partly explain the rise in acute admissions
observed in the 2013–2014 period, which can also be attributable to
an overall increase in the incidence of UC in Australia.1
The introduction of TNF-α inhibitors also resulted in a
shorter LOS for patients who were admitted with severe UC. For
patients admitted with moderate disease, there was no difference
in LOS, which may reﬂect the fact that only one patient in our
cohort with moderate disease was given Inﬂiximab. Furthermore,
the average LOS was signiﬁcantly longer in patients who underwent emergency operations when compared to patients who
underwent emergent operations or had no surgery, which is consistent with data published by Patel et al.12 This has therefore
had signiﬁcant implications on local resources at this institution.
The cost of a 100 mg single dose of Inﬂiximab in
Australia is $507.42.14 Due to the previously noted high cost of
each dose of Inﬂiximab ($507.42), it is a highly regulated drug
and is reserved only for severe ﬂares of UC that are resistant to
standard medical therapy. However, it is likely that the reduced
number of operations, LOS, and complications in our cohort of
patients in the post-Inﬂiximab era will result in tangible savings
to the Australian health-care system, which may balance the cost
of TNF-/ therapy. Further research is required to conﬁrm the
cost-effectiveness of the use of Inﬂiximab in UC.
Limitations. This study was not without limitations. Being a
retrospective study, all data were obtained via medical notes and
patient information databases available. The data are therefore limited to the accuracy of the documentation on these platforms. This
may have had implications, particularly regarding the accuracy of
staging of the severity of acute ﬂares. Our institution is one of
three public tertiary referral centers in Western Australia. Patients
often attend other institutions in the emergency setting, which may
have affected the accuracy of the number of admissions with UC
in our catchment area per year. Compounding this, some patients
may have eventually had their treatment at private hospitals whose
records are beyond the ethical approval of this study.

16

p < 0.001

p = 0.861

14
12
10
8
6
4
2
0
Pre-2008

2008 and onward

Moderate UC

Pre-2008

2008 and onward

Severe UC

Figure 3 Average length of stay for moderate and severe ulcerative
colitis (UC) pre- and post-2008. The error bars represent the 95% CI.

Conclusions
Overall, the need for emergency and emergent operations has drastically reduced at our institution with the introduction of TNF-alpha
inhibitors. For a patient who presents with severe colitis, the use of
this medication has increased the likelihood that he or she could be
managed medically or with an emergent/elective operation rather
than an emergency operation with all its associated risks and complications. This study has conﬁrmed the efﬁcacy of TNF-alpha
inhibitors in reducing colectomy rates at our institution. This has
elicited a paradigm change in the management of patients presenting
with acute severe ﬂares of UC, which were previously associated
with signiﬁcant morbidity. Further cost analysis research would justify its use even more and assess the ﬁnancial impact of TNF-alpha
inhibitors on the hospital system and patients.
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